Simultaneous pembrolizumab-induced myasthenia gravis and myocarditis in a patient with metastatic bladder cancer: A case report
| Autor: | Koji Iinuma, Takuya Koie, Shigeaki Yokoi, Yuka Muramatsu Maekawa, Manabu Takai, Tomohiro Tsuchiya, Daiki Kato, Keita Nakane |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2020 |
| Předmět: |
medicine.medical_specialty
Myocarditis AchR acetylcholine receptor Urology 030232 urology & nephrology Edrophonium Pembrolizumab lcsh:RC870-923 Gastroenterology AEs adverse events MG myasthenia gravis 03 medical and health sciences 0302 clinical medicine Ptosis MuSK anti-muscle-specific kinase Prednisone Internal medicine medicine irAEs immune-related AEs Diplopia Ejection fraction business.industry medicine.disease lcsh:Diseases of the genitourinary system. Urology Myasthenia gravis CT computed tomography IVIG intravenous immunoglobulin Oncology 030220 oncology & carcinogenesis medicine.symptom business medicine.drug |
| Zdroj: | Urology Case Reports Urology Case Reports, Vol 31, Iss, Pp-(2020) |
| ISSN: | 2214-4420 |
| Popis: | We report a fatal case of pembrolizumab-induced myasthenia gravis and myocarditis in a patient with metastatic bladder cancer. A 77-year-old man was aware of eye ptosis and diplopia after three weeks from first infusion of pembrolizumab, an anti-programmed cell death protein 1 monoclonal antibodies. He was diagnosed with myasthenia gravis, because he was positive on the edrophonium test and acetylcholine receptor antibody. As his echocardiography also revealed diffuse loss in wall motion with ejection fraction 29%, he was strongly suspected myocarditis. Although he was treated with prednisone and intravenous immunoglobulin, he was suddenly in cardiac arrest and passed away. Highlights • Appropriate therapy for pembrolizumab-induced MG and myocarditis should rapidly need. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|